NKGen Biotech shares are trading higher after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer's disease.
Portfolio Pulse from Benzinga Newsdesk
NKGen Biotech shares are trading higher after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer's disease.
May 20, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NKGen Biotech shares are trading higher following the clearance of its SNK01 NK Cell Therapy for a Phase 2 trial in Alzheimer's disease.
The clearance for a Phase 2 trial in Alzheimer's disease is a significant milestone for NKGen Biotech, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100